阿托伐他汀对急性冠脉综合症患者血清妊娠相关蛋白-A及C反应蛋白的影响

摘要：目的 探讨阿托伐他汀对急性冠脉综合症患者血清妊娠相关蛋白-A(pregnancy-associated plasma protein-A，PAPP-A)和C反应蛋白（c-reative protein，CRP）的影响。方法 测定90例正常对照组和105例急性冠脉综合症患者血清PAPP-A、CRP的浓度，所得结果进行统计分析。急性冠脉综合症组患者随机分为两组，分别应用阿托伐他汀20mg、10mg治疗一周后再次测定PAPP-A及CRP浓度，观察不同剂量之间的治疗效果。结果：急性冠脉综合症组患者PAPP-A及CRP浓度显著高于正常对照组；阿托伐他汀20mg治疗可显著降低PAPP-A及CRP浓度，与阿托伐他汀10mg相比有统计学意义(P＜O．05)。结论：急性冠脉综合症患者PAPP-A和CRP血浆水平明显升高，阿托伐他汀可以降低ACS患者血清PAPP-A和CRP浓度，减轻炎症反应稳定冠脉粥样硬化斑块，并且这种机制与剂量相关。

Effects of Atorvastatin on Serum Concentration of PAPP-A and C-reative Protein Levels with Acute Coronary Syndrome

Abstract：Objectives To investigate the effects of atorvastatin on selllm concentration of PAPP—A and c-reative protein(CRP) levels in patients with acute coronary syndrome．Methods We measured the serum concentrations of PAPP-A、CRP levels before and after treatment with atorvastatin 20mg、10mg in 105 ACS cases and 90 cases of control group．Results PAPP-A and CRP levels in patients with ACS were significantly higher than control group patients before intervention. There was obvious difference of PAPP-A、CRP levels in atorvastatin 20mg group and atorvastatin 10mg group after one week treatment(P＜O．05). Conclusions PAPP-A and CRP levels in patients with ACS were significantly greater than control group. Atorvastatin can significantly reduce the PAPP-A and CRP levels in ACS patients, especially in atorvastatin 20mg group.